## Supplementary Material

## Clinical outcomes following balloon aortic valvuloplasty

Anda Bularga MD<sup>1</sup>, Rong Bing MBBS<sup>1,2</sup>, Anoop S. V. Shah MD<sup>1,2</sup>, Philip D. Adamson MBBS<sup>2,3</sup>, Miles Behan MD<sup>2</sup>, David E. Newby MD<sup>1,2</sup>, Andrew D. Flapan MD<sup>2</sup>, Neal Uren MD<sup>2</sup>, Nick Cruden MD<sup>2</sup>

<sup>1</sup> BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.

<sup>2</sup> Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, UK

<sup>3</sup> Christchurch Heart Institute, University of Otago, New Zealand

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

Appendix 1: ICD-10 codes for secondary outcomes at 30 days and 1 year

**Myocardial Infarction:** I210, I2100, I2101, I2109, I211, I2110, I2111, I2119, I212, I2120, I2121, I2129, I213, I2130, I2131, I2139, I214, I2140, I2141, I2149, I219, I2190, I2191, I2199, I220, I2200, I2201, I2209, I221, I2210, I2211, I2219, I228, I2280, I2281, I2289, I229, I2290, I2291, I2299

**Stroke:** 1609, 1602, 1638 D, 1614, 1600, 1631 D, 163, 1631, 1632, 1607, 1616, 1633, 16390, 164X, 1603, 1632 D, 1635, 1608, 1618, 1634, 1606, 1639 D, 1630, 164X D, 1613, 1612, 1619, 1620, 1615, 1610

Heart failure: 1509, 1500, 1500 D, 1501, 15009, 1501 D, 1426, 15010, 15090, 1110, 15000, 15019, 15099, 15091, 15001, 15001D, 1509 D, 15011, 15009D, 1130, 1132, 15000D, 15010D, 15091D, 15019D, 15099D, 11329, 15090D, 11109, 11101, 11100, 15011D, 11320, 11321, 11300, 11309

## Acute Renal Failure: N17

**Bleeding:** H431, K920, K264, R042, K922, I601, I609, K921, I620, K625, K260, I629, K226, N938, S066, O041, I608, N939, T810, S0650, K250, I607, S065, I602, K290, I850, K266, S0660, K254, I603, H450 A, I604, I621, I606, K291, S0640, O722, O209, I230, I605, K262, R048, K284, K276, S0641, K256, H356, K274, O071, S064, O208, O036, S0651, O721, K252, R041, K286, S0661, K270, I312, N837, O081, O031, K280, O046, O720, O469, R049, O902, I690, K272, I609 D, O076, I692, P261, O061, O051, K282, O066, O460, P269, O717, I607D

Year	Number of index BAV procedures per	Number of patients undergoing repe
	year	intervention
2010	3	0
2011	5	2
2012	13	8
2013	26	9
2014	34	17
2015	27	9
2016	32	12
2017	22	9
2018	5	1

	Hazard ratio	p-value	
Age	0.92 (0.75-1.13)	0.404	
Sex (male)	1.50 (1.03-2.19)	0.034	
Aypertension	1.10 (0.75-1.61)	0.617	
schaemic heart disease	1.40 (0.96-2.03)	0.083	
Atrial fibrillation	1.10 (0.75-1.60)	0.628	
Chronic Kidney Disease	1.46 (0.91-2.37)	0.12	
Diabetes	1.07 (0.70-1.63)	0.762	
Pulmonary disease	1.01 (0.67-1.52)	0.959	
Cerebrovascular disease	1.32 (0.76-2.27)	0.323	
Priority - Elective	Reference		
Urgent	1.55 (1.04-2.30)	0.03	
Emergency	2.08 (1.10-3.92)	0.024	
LVEF category >50%	Reference		
30-50%	1.82 (1.14-2.89)	0.012	
<30%	2.06 (1.31-3.25)	0.002	

	Events
MI (%)	8 (4.8)
Stroke (%)	2 (1.2)
Heart Failure (%)	9 (5.4)
Acute Renal Failure (%)	14 (8.4)
Bleeding (%)	1 (0.6)
All-cause mortality (%)	18 (10.8)

Supplementary table 4: Baseline characteristics according to repeat intervention type						
	Overall BAV		TAVI	SAVR	p-value	
N	167	9	42	16		
Age [IQR]	80.0 [73.0, 86.0]	74.0 [65.0, 78.0]	84.0 [73.2, 89.5]	74.0 [71.0, 78.2]	0.001	
Male (%)	87 (52.1)	5 (55.6)	21 (50.0)	8 (50.0)	0.981	
Hypertension (%)	100 (59.9)	6 (66.7)	23 (54.8)	9 (56.2)	0.824	
Ischaemic heart disease (%)	67 (40.1)	5 (55.6)	17 (40.5)	6 (37.5)	0.803	
Previous MI (%)	38 (22.8)	2 (22.2)	8 (19.0)	2 (12.5)	0.596	
Previous PCI (%)	22 (13.2)	2 (22.2)	4 (9.5)	1 (6.2)	0.553	
Previous CABG (%)	31 (18.6)	3 (33.3)	12 (28.6)	2 (12.5)	0.119	
Cerebrovascular disease (%)	20 (12.0)	0 (0.0)	1 (2.4)	3 (18.8)	0.068	
eGFR (ml/min/1.73m2)					0.315	
>60 (%)	88 (52.7)	4 (44.4)	27 (64.3)	7 (43.8)		
30-59 (%)	55 (32.9)	4 (44.4)	14 (33.3)	4 (25.0)		
<30 (%)	20 (12.0)	1 (11.1)	1 (2.4)	4 (25.0)		
Haemodialysis (%)	4 (2.4)	0 (0.0)	0 (0.0)	1 (6.2)		
Diabetes (%)	43 (25.7)	3 (33.3)	10 (23.8)	2 (12.5)	0.554	
Pulmonary disease (%)	47 (28.1)	2 (22.2)	14 (33.3)	4 (25.0)	0.835	
Peripheral vascular disease (%)	22 (13.2)	0 (0.0)	10 (23.8)	0 (0.0)	0.045	
Pacemaker (%)	9 (5.4)	0 (0.0)	1 (2.4)	0 (0.0)	0.320	
Smoking history					0.728	
No (%)	101 (68.2)	6 (66.7)	27 (69.2)	12 (85.7)		
Ex (%)	38 (25.7)	3 (33.3)	9 (23.1)	2 (14.3)		

Yes (%)	9 (6.1)	0 (0.0)	3 (7.7)	0 (0.0)	
Priority of index BAV					< 0.001
Elective (%)	79 (47)	3 (33.3)	27 (64.3)	4 (25.0)	
Urgent (%)	72 (43.4)	5 (55.6)	15 (35.7)	4 (25.0)	
Emergency (%)	16 (9.6)	1 (11.1)	0 (0.0)	8 (50.0)	
LVEF					0.394
>50%	64 (38.8)	4 (44.4)	21 (51.2)	7 (43.8)	
30-50%	47 (28.5)	2 (22.2)	12 (29.3)	4 (25.0)	
<30%	54 (32.7)	3 (33.3)	8 (19.5)	5 (31.2)	
Peak gradient (mmHg) [IQR]	70.0 [57.0, 80.0]	68.0 [55.0, 76.5]	64.0 [53.5, 78.5]	75.0 [64.5, 90.0]	0.065
Mean gradient (mmHg) [IQR]	42.0 [30.0, 50.0]	40.0 [30.0, 48.0]	36.0 [29.0, 52.0]	49.0 [42.5, 55.0]	0.005
(IQR=interquartile range, MI=myocardia surgery, eGFR=estimated glomerular filtra					

Supplementary table 5 – All-cause mortality stratified by repeat intervention					
	Overall	None	Repeat BAV	TAVI	SAVR
N	167	100	9	42	16
Mortality at 30 days (%)	18 (11%)	16 (16%)	3 (33%)	3 (7%)	1 (6%)
Mortality at 12 months (%)	72 (43%)	60 (60%)	8 (89%)	6 (14%)	3 (19%)

(N=number, BAV=balloon aortic valvuloplasty, TAVI= transcatheter aortic valve implantation, SAVR=surgical aortic valve replacement)

## Supplementary figure 1: Multivariable Cox proportional hazard survival stratified by baseline ejection

fraction.

